AI for Drug Discovery Landscape Overview Q3/2018

Deep Knowledge Analytics is pleased to announce the publication of its most advanced industry analytical report to date: AI for Drug Discovery, Biomarker Development and Advanced R&D 2018 Q3.​

 

The large majority of the report, including AI for Drug Discovery Landscape Overview (Industry Developments Q3 2018) and Novel Technologies & Trends, and Appendices (which feature profiles of 125 Companies, 260 Investors, 30 Biopharma and IT/Tech Corporations, and 20 leading R&D Centres active in the AI for Drug Discovery space), has been made available free of charge. First part delivers a summary of the most important recent industry events, including coverage of the most important BioPharma and IT/Tech corporations active in the space, government initiatives aiming to accelerate the dynamic of industry progress in the USA, UK, EU and Asia-Pacific region, industry-specific conferences and journalists, and a regional comparison of industry activity that summarizes which countries are currently at the forefront of activity, which ones are lagging behind, and which ones are showing evidence of rapidly increasing activity in the years to come. Second part provides in-depth coverage of the science and technology behind the industry, analysis of emerging subsectors and new application within the industry (including the convergence of AI with blockchain, digital medicine and Longevity technologies).​